JenaValve Technology said yesterday that it raised nearly $15 million for the transcatheter aortic valve replacement it’s developing.
The Irvine, Calif.-based company makes the the Everdur valve and Coronatix delivery catheter to treat aortic stenosis and aortic regurgitation. In a regulatory filing, JenaValve said it pulled in $14.5 million in an equity round that began June 6. The round involved 10 unnamed investors, according to the filing.
Representatives for the company did not immediately return emails seeking comment.
Late last year the FDA approved the expansion of an investigational device exemption trial for the JenaValve system, from 20 extreme- or high-risk patients to 80 patients with either aortic stenosis or aortic regurgitation. JenaValve has said the IDE studies are part of its larger CE Mark program in Europe and New Zealand.
In January the company named former ReVision Optics president & CEO John Kilcoyne as its new chief executive, replacing Dr. Victoria Carr-Brendell, who left to join Sonova Holding AG (SIX:SOON).
